Primary content

Related to 'Chemotherapy'

Introduction of temozolomide into standard care in 2005 coincided with improvements in survival and a rapid increase in temozolomide prescribing.

Between 2018 and 2040, the number of patients requiring first-course chemotherapy annually will increase from 9·8 million to 15·0 million, a relative increase of 53%. Strategic investments in chemotherapy service provision and cancer physicians will be needed to meet the projected increased demand.

Emergency hospitalisations following chemotherapy for early breast cancer were relatively common, especially following docetaxel-containing protocols.

Consultation with an oncologist mitigated most of the sociodemographic and service-related disparities in chemotherapy use. There is a need to establish referral pathways to ensure that all patients have the opportunity to discuss treatment options with a medical oncologist.

eviQ was highly regarded by the Australian medical oncologists who responded to the survey. Usage of eviQ had a positive impact on knowledge, practice and promoted better patient-centered care.

Receipt of standard adjuvant chemotherapy at a relative dose intensity of 70% or less was associated with poorer survival in women with epithelial ovarian cancer.

eviQ provides up to date, evidence-based treatment information for health professionals - find out how protocols are developed